Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. - Wikidata - wikimedia - TriplyDB

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

http://www.wikidata.org/entity/Q34155719

about

Immune stimulation following dermal exposure to unsintered indium tin oxide A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor.Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FcεRI.Carboplatin-induced hypersensitivity reaction.Oxaliplatin-induced lung injury with allergic reaction.Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions Hypersensitivity to oxaliplatin: clinical features and risk factors.Serum lactate dehydrogenase levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions.Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization.Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy.4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions.Oxaliplatin for the treatment of ovarian cancer.Adjunct Histamine Blockers as Premedications to Prevent Carboplatin Hypersensitivity Reactions.Hypersensitivity to Carboplatin in Children with Malignancy.Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer.Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.Hypotension due to Chemotherapy in a Patient with Small Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome Undergoing Hemodialysis: A First Case Report.Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma.Designing new iridium(iii) arene complexes of naphthoquinone derivatives as anticancer agents: a structure-activity relationship study.Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report.Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.Platinum or nonplatinum in recurrent ovarian cancer: that is the question.Iridium(I) Compounds as Prospective Anticancer Agents: Solution Chemistry, Antiproliferative Profiles and Protein Interactions for a Series of Iridium(I) N-Heterocyclic Carbene Complexes.Pediatric Optic Pathway/Hypothalamic Glioma.Recurrent cisplatin hypersensitivity reaction after first exposure: A case report.Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy.Impact of drug formulation and free platinum/cisplatin ratio on hypersensitivity reactions to cisplatin: formulation matters

P2860

Q23916383-1676761F-17BC-49D9-8EE3-9A1125E35352 Q33400418-12F6A893-4DD6-44E9-A2EF-548C24E77EF5 Q33410375-E272A4D5-C897-462F-91A4-D7B406904C8E Q33600062-439AD554-5ACF-480B-804D-586CAB56967D Q33650643-047F2603-27D0-4CB8-8B87-8FEDCC9253E1 Q33801643-A7BBF3ED-89B7-4E9C-A900-A0CF65B9D805 Q33911016-D91FEF74-E18A-4D01-829B-F61F202F681C Q33982751-9A868C7E-BA11-474F-9305-6B9CEDA7B0A0 Q34648284-7776FA0C-F20A-4C57-80DB-61A4C63C3316 Q35713385-4D7CEB07-FAD9-47A0-AC5F-6D3C8BBF891F Q35998211-526EF80D-5FC3-48AB-A0F8-2723CC25CCE4 Q36654724-FB5199A1-1157-4540-9757-FA2F3017732A Q37111145-63ED29BC-640F-4E6D-85AB-EDBF76DCD7E5 Q37497459-7AC272AC-8137-41CA-AE12-A3CA686CDB3C Q37730274-F90C7669-96B5-400A-A607-66151D361836 Q37740616-5C9F67E9-8541-4C01-9F70-1358144BB5CA Q38009188-C1FC0C7A-A628-4BED-87F7-06753D78AD58 Q38132699-2D3AEEB6-7E6E-4316-9328-49FB86702838 Q38230264-0480BF4C-6B58-4FAF-89FF-7A1BAA3F5788 Q38393480-672FE2A2-398B-4643-BD4C-8D63E1959EC8 Q38540596-B1AC17B8-D7FE-4CDB-AA92-2EBBE5E21B97 Q38779659-67137312-E530-4636-815B-CC6F6957274A Q38817913-8A809E3A-30C8-44E7-A2A1-26704FA86A65 Q38996049-658DCA2A-30A0-4A93-BCF3-E8DB0C1D7399 Q39179349-DBCAECF1-BEE5-4A88-9A8B-E5162711F373 Q39282981-A4ACA934-B3A8-4CC9-AE72-A26E1E1289A3 Q42581091-C6EAEA99-E647-47FC-8BAA-DEE0AFAAF122 Q44842257-6C15B0D7-99DE-4167-A34E-FDFEF8C83FCA Q46282808-A29A9CF4-BA4E-4E0F-BE42-193127A8B34C Q46425575-EB00FD24-C32E-4EB3-BF7C-B00108FB33CB Q47124163-9AA456C8-BB1A-4B28-9A19-5CD72066821E Q47576894-8101E325-CB0E-45D9-91E5-202BBA3250DF Q47865412-96B8046F-82B1-43D4-A04D-0A4DADDC61E5 Q47903289-8FB4D671-F85A-43B6-AC3D-6C8164502F5E Q48148699-D6694430-3DF1-433F-99B2-14D92B39BFD9 Q49203220-ACD0F02F-2247-494C-9C9E-7CF7203F392F Q50097707-6E373C8B-82A8-49B5-BE4E-C4CC548F6B45 Q55459950-D74D86AC-0D19-46BC-9504-62187CA9ACA7 Q56763984-6574B6A7-4FD8-4061-81D1-B13115615956

P2860

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

http://www.wikidata.org/entity/Q34155719

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Hypersensitivity reactions ass ...... c agents: a systematic review.

@ast

Hypersensitivity reactions ass ...... c agents: a systematic review.

@en

Hypersensitivity reactions ass ...... c agents: a systematic review.

@nl

type

label

Hypersensitivity reactions ass ...... c agents: a systematic review.

@ast

Hypersensitivity reactions ass ...... c agents: a systematic review.

@en

Hypersensitivity reactions ass ...... c agents: a systematic review.

@nl

prefLabel

Hypersensitivity reactions ass ...... c agents: a systematic review.

@ast

Hypersensitivity reactions ass ...... c agents: a systematic review.

@en

Hypersensitivity reactions ass ...... c agents: a systematic review.

@nl

P1433

Q34155719-47E57BEC-18F4-49E6-8B37-DC660A8B6ECE

P1476

Q34155719-B8A760C3-E58E-40B4-A9F5-157EE5FA2CB1

P2093

Q34155719-493DDADE-F834-441F-BB0A-74F323262C63

Q34155719-7C9FB168-DEF7-4A7C-B1F6-4B13A750662F

Q34155719-A045FC61-7C76-4EF7-8695-647DB5AD67E0

Q34155719-A6294E95-06D2-4EC4-9023-10A58AA26A68

Q34155719-F371BD16-D462-4481-8F70-943791430973

P2860

Q34155719-02016340-684C-4ED5-ABE6-40243283234E

Q34155719-042F3101-2F0D-4B73-9D22-F9B724730CE3

Q34155719-0A609CE5-EBE0-4920-BCEE-A4ACA1258F50

Q34155719-0C0A0140-F15D-4798-91FF-4C623F077D4C

Q34155719-0CCFD5C9-8112-4091-9080-1697A3BB875D

Q34155719-0DB268B8-C1B3-47E8-AAF1-6B9EA5874530

Q34155719-13A59307-C627-4983-9E72-2502C5DA362C

Q34155719-14230659-6247-4932-B1A0-5E3D32724A14

Q34155719-19787E95-5EE1-42C5-9233-2E255AC4D0A2

Q34155719-19918F83-332C-40BF-B845-62F7F3E50372

P304

Q34155719-6B73C2DC-DFD4-439C-B066-A6A5E4B6D08F

P31

Q34155719-6856FC38-5370-447B-976F-FFED759EA313

P356

Q34155719-5919CFC9-3182-48DC-9233-428A79BD67F6

P478

Q34155719-9C3767DF-39D5-44DF-AC0B-F3C92BBB3CEB

P577

Q34155719-AC6F5010-8547-4FC3-B757-0E5DB47B54F8

P5875

Q34155719-7144C41B-B727-4B60-AFFF-833C7A61AF82

P698

Q34155719-69B96C41-B7EA-4D56-B256-72B3EEED2C9E

P932

Q34155719-58970E91-ABDA-4D7E-9313-D5AB0D67BF04

P356

P1433

Metal-Based Drugs

P1476

Hypersensitivity reactions ass ...... c agents: a systematic review.

@en

P2093

Ekaterini Syrigou

http://www.w3.org/2001/XMLSchema#string

Ioannis Kaklamanos

http://www.w3.org/2001/XMLSchema#string

Leonidas Manolopoulos

http://www.w3.org/2001/XMLSchema#string

Muhammad Wasif Saif

http://www.w3.org/2001/XMLSchema#string

Nektaria Makrilia

http://www.w3.org/2001/XMLSchema#string

P2860

Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.

Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.

Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.

Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.

Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.

Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

P304

707-718

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2010/207084

http://www.w3.org/2001/XMLSchema#string

P478

2010

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47157643

http://www.w3.org/2001/XMLSchema#string

P698

20886011

http://www.w3.org/2001/XMLSchema#string

P932

2945654

http://www.w3.org/2001/XMLSchema#string